Clinical trial
Rimonabant to Reduce Alcohol Consumption
NCT00075205 · National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH · Completed
Key facts
| NCT number | NCT00075205 |
|---|---|
| Title | Rimonabant to Reduce Alcohol Consumption |
| Official title | Clinical Trial of the Cannabinoid CB1 Receptor Antagonist, SR141716 (Rimonabant), to Reduce Voluntary Ethanol Drinking in Healthy, Non-Treatment Seeking Individuals Who Consume Between 20 and 50 Drinks Per Week |
| Lead sponsor | National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH |
| Collaborators | Sanofi-Synthelabo Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Healthy, Alcohol Drinking |
| Intervention type | Drug |
| Interventions | SR141716 (Rimonabant) |
| Enrollment | 54 |
| Start date | Dec 31, 2003 |
| Primary completion | Mar 15, 2007 |
| Completion | Mar 15, 2007 |
| First posted | Jan 6, 2004 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: